Diagnosis of renal artery stenosis (RAS) should be discussed in numerous clinical situations including refractory high blood pressure (HBP), HBP in a polyvascular patient, degradation of renal function following renin angiotensin inhibitor or flash pulmonary edema. Ultrasound-doppler coupled with gadolinium-enhanced MR or CT angiography has proven adequate for most patients with RAS. Digital subtraction angiography should be limited to revascularisation procedures. Functional testing are not sensitive or specific enough because the degree of renin activation differs widely among patients with RAS. Renal percutaneous angioplasty induces a light to moderate decrease in blood pressure, has no effect on renal function but allows to reduce the number of anti-hypertensive drugs. Stenting completed angioplasty is worthwhile in most patients with atherosclerotic RAS. ACE inhibitors decrease mortality and increase renal function in patients with RAS.

In critical limb ischemia, the aim of the treatment is to increase the arterial blood flow in the affected limb in order to relieve pain, heal trophic lesions, and avoid amputation. In patients in whom revascularization is not possible, medical treatment can occasionally be considered although it may not prevent limb loss in many patients. Medical strategies include the use of antalgics frequently opioids, antiplatet agents and prevention of venous thromboembolism. Selected patients may benefit from intravenous prostanoids, although their efficacy is unconstant. Maintenance of the bed in a dependant position may increase blood perfusion in the affected limbs. Gene and cell therapies, although promissing strategies, are currently evaluated in large clinical trials.

Dans l'ischémie critique chronique des membres inférieurs (ICCMI), le but du traitement est d'augmenter la perfusion artérielle du membre touché afin de réduire les phénomènes douloureux, de cicatriser les troubles trophiques et d'éviter l'amputation du membre. Chez les patients ne pouvant bénéficier d'une revascularisation, un traitement médical doit être mis en place cependant que son efficacité n'est pas régulière et ne permet pas d'éviter l'amputation chez un nombre important de malades. Les traitements médicamenteux de l'ICCMI comprennent les antalgiques souvent opiacés, les antiagrégants plaquettaires, les antibiotiques et, la prévention de la maladie veineuse thromboembolique. Certains patients peuvent bénéficier de l'administration intraveineuse d'analogues pharmacologiquement stables des prostaglandines, cependant leur efficacité est inconstante. La mise en position déclive du lit améliore la perfusion distale du membre atteint. Les thérapies géniques et cellulaires, stratégies thérapeutiques prometteuses, sont en cours d'évaluation dans des essais cliniques de grande taille.

Raynaud's phenomenon and digital necrosis of the fingers are rare complications of hypereosinophilia. We report a case of a smoking male who developed Raynaud's phenomenon and digital necrosis of the fingers associated with idiopathic hypereosinophilia with angiographically documented occlusion of small and medium arteries of the extremities. The eosinophils may play a thrombotic role in vascular pathology and eosinophil blood count should be checked when investigating patients with digital gangrene.

The French network of Regional Pharmacovigilance Centres evaluated in 1997 the prevalence of adverse effects of drugs (AED). In 1998, and again with the support of the French Drug Agency, in collaboration with the company CEMKA for economic evaluations, the incidence of AED-related hospitalizations in the medical department of French public hospitals was studied. The evaluation was performed over 14 consecutive days in 62 hospital departments, which were selected randomly. The total number of 3137 patients were hospitalized for a mean duration of 9 days and they were using a mean number of six different drugs. Taking into account the number of about 4 million patients admitted per year in the hospitals represented, it was estimated that the total number of AED-related hospitalizations amounts to about 130 000 annually (CI95%: 100 916-156 620). Using established cost calculations for hospitalized days (AP-HP, results of 1996) the mean cost for an AED-related hospitalization was estimated to be about FF16 000.

The French network of Regional Pharmacovigilance Centres evaluated in 1997 the prevalence of adverse effects of drugs (AED). In 1998, and again with the support of the French Drug Agency, in collaboration with the company CEMKA for economic evaluations, the incidence of AED-related hospitalizations in the medical department of French public hospitals was studied. The evaluation was performed over 14 consecutive days in 62 hospital departments, which were selected randomly. The total number of 3137 patients were hospitalized for a mean duration of 9 days and they were using a mean number of six different drugs. Taking into account the number of about 4 million patients admitted per year in the hospitals represented, it was estimated that the total number of AED-related hospitalizations amounts to about 130,000 annually (CI95%: 100,916-156,620). Using established cost calculations for hospitalized days (AP-HP, results of 1996) the mean cost for an AED-related hospitalization was estimated to be about FF16,000.

The French network of Regional Centres of Pharmacovigilance has made an estimation of the occurrence of adverse drug reactions in a representative sample of patients in French public hospitals (departments of medicine, of surgery and of geriatrics). The study looked at one specific day in the spring of 1997. Each observed case of adverse drug reaction was validated. The total sample comprised 2132 patients of whom 969 were in a university hospital and 1163 in a general hospital. The hospitals and units concerned are representative of the country as a whole. One adverse drug reaction at least was present for 221 patients on the day of the investigation. This means a prevalence rate of 10.3 per cent (95 per cent CI: 8.7 to 11.9 per cent). In 33 per cent of cases (95 per cent CI: 26 to 42 per cent), the observed effects were rated as serious. From an incidence rate of 1.8 per cent (95 per cent CI: 1.0 to 25 per cent) on one specified day it can be estimated that in France an adverse drug reaction will occur in about 1,300,000 patients per year during a stay in hospital.

The French network of Regional Centres of Pharmacovigilance has made an estimation of the occurrence of adverse drug reactions in a representative sample of patients in French public hospitals (departments of medicine, of surgery and of geriatrics). The study looked at one specific day in the spring of 1997. Each observed case of adverse drug reaction was validated. The total sample comprised 2132 patients of whom 969 were in a university hospital and 1163 in a general hospital. The hospitals and units concerned are representative of the country as a whole. One adverse drug reaction at least was present for 221 patients On the day of the investigation. This means a prevalence rate of 10.3 per cent (95 per cent CI: 8.7 to 11.9 per cent). In 33 per cent of cases (95 per cent CI: 26 to 42 per cent), the observed effects were rated as serious. From an incidence rate of 1.8 per cent (95 per cent CI: 1.0 to 25 per cent) on one specified day it can be estimated that in France an adverse drug reaction will occur in about 1 300 000 patients per year during a stay in hospital.

Summary— The increase in renin secretion and the induction of the converting enzyme (ACE) observed during treatment by ACE inhibitors (CEIs) could result in increased angiotensin II (ang II) synthesis when the treatment is stopped. The object of this study was to compare changes in the components of the renin‐angiotensin system with changes in arterial pressure in hypertensives, following the cessation of long‐term ramipril treatment. Twenty hypertensives, treated for at least three months with ramipril, in monotherapy for the last three weeks, were randomly allocated to two parallel groups and received for fifteen days, on a double‐bind basis, either a placebo (withdrawal group W, n = 12) or ramipril at the previous doses (treated group T, n = 8). Blood pressure was measured using four different techniques. The active renin (AR), angiotensinogen, angiotensin I (ang I), angiotensin II (ang II) and aldosterone plasma concentrations were measured, as was plasma angiotensin I converting enzyme (ACE) activity in vitro (colorimetric and fluorimetric method) and in vivo (the ang II/ang I ratio). The biological effects of cessation of long‐term ramipril treatment in hypertensives were a decline in AR and angiotensin I concentrations, an increase in ACE activity and no significant changes in angiotensinogen, angiotensin II and aldosterone levels. Fifteen days after withdrawal, the different parameters of the renin‐angiotensin system appear to have returned to basal value. A slow rise in blood pressure was also observed but no rebound increase was noted during the 15 days neither in angiotensin II levels nor in blood pressure. Following the cessation of prolonged ramipril treatment, in vivo converting enzyme inhibition disappears slowly, probably on account of the slow tight binding inhibitor properties of ramiprilat, the active metabolite of this CEI. The gradual decline in AR plasma levels, together with the prolonged ACE inhibition as measured in vivo by the ang II/ang I ratio, explains the absence of a rise in ang II synthesis.

Stephan, D.; Welsch, M.; Decker, N.; Brulé, J. M.; Jahn, C.; Grima, M.; Imbs, J. L. Author Information

The aim of this study was to demonstrate the diagnostic value of changes in active renin concentration during the captopril test (measurements of plasmatic active renin concentrations, before 12.5 or 37.5 mg of captopril p.o., and 30 and 90 minutes after) in order to screen a significant renal artery stenosis. After a renal angiography, 88 hypertensive patients suspected of renovascular hypertension were classified according to the percentage of stenosis in the main renal artery: class I (< 30% - n = 50), II (30 to < 75% - n = 21), III (75 to < 90% - n = 8) and IV (90 to 100% - n = 11). The results of the captopril test were compared to those of renal angiography. The active renin before the test (basal AR), the greater increase in active renin after captopril (max AR), the difference between max AR and basal AR (DIF) and the active renin relative change after the test (RC) were compared in the 4 classes (ANOVA). There were no differences in diastolic blood pressure (> or = 90 mmHg) natriuresis (100 mmol/24 h in mean) between these different classes. The basal AR, the max AR, the DIF and the RC significantly differed between the 4 classes. They were greater in class III and IV than in class I. The positive criteria for the captopril test were max AR, DIF and RC. The positivity thresholds were max AR > or = 70 ng/l, DIF > or = 50 ng/l and RC > or = 165% (upper limit in the class I 95% confidence interval for each criterion).(ABSTRACT TRUNCATED AT 250 WORDS)

The aim of this study was to demonstrate the diagnostic value of changes in active renin concentration during the captopril test (measurements of plasmatic active renin concentrations, before 12.5 or 37.5 mg of captopril p.o., and 30 and 90 minutes after) in order to screen a significant renal artery stenosis. After a renal angiography, 88 hypertensive patients suspected of renovascular hypertension were classified according to the percentage of stenosis in the main renal artery : class I (< 30 % - n = 50), II (30 to < 75 % - n = 2 1), III (75 to < 90 % - n = 8) and IV (90 to 100 % - n = 11). The results of the captopril test were compared to those of renal angiography. The active renin before the test (basal AR), the greater increase in active renin after captopril (max AR), the difference between max AR and basal AR (DIF) and the active renin relative change after the test (RC) were compared in the 4 classes (ANOVA). There were no differences in diastolic blood presure (greater-than-or-equal-to 90 mmHg) natriuresis (100 mmol/24 h in mean) between these different classes. The basal AR, the max AR, the DIF and the RC significantly differed between the 4 classes.They were greater in class III and IV than in class I. The positive criteria for the captopril test were max AR, DIF and RC. The positivity thresholds were max AR greater-than-or-equal-to 70 ng/l, DIF greater-than-or-equal-to 50 ng/l and RC greater-than-or-equal-to 165 % (upper limit in the class I 95 % confidence interval for each criterion). In this study captopril test sensitivity was 68,4 %, specificity 88 %, the positive predictive value 60 % and the negative predictive value 98 %.